Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.

Rajiv AgarwalGerasimos FilippatosBertram PittStefan D AnkerEllen BurgessAmer JosephPeter KolkhofChristina NowackMartin Gebel Luis M Ruilope George L Bakrisnull null

Published in: European heart journal (2022)

Finerenone reduces the risk of clinical cardiovascular outcomes and kidney disease progression in a broad range of patients with chronic kidney disease and type 2 diabetes. Screening for albuminuria to identify at-risk patients among patients with type 2 diabetes facilitates reduction of both cardiovascular and kidney disease burden.

Keyphrases

end stage renal disease
chronic kidney disease
type diabetes
peritoneal dialysis
newly diagnosed
ejection fraction
prognostic factors
cardiovascular disease
insulin resistance
patient reported outcomes
risk factors
skeletal muscle
weight loss